These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 23216053)

  • 1. Emerging VEGF-receptor inhibitors for colorectal cancer.
    Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
    Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer.
    Troiani T; Martinelli E; Orditura M; De Vita F; Ciardiello F; Morgillo F
    Expert Opin Investig Drugs; 2012 Jul; 21(7):949-59. PubMed ID: 22612461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
    Mitchell EP
    Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept].
    Kato S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):6-9. PubMed ID: 23306912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management.
    Cartwright TH
    Clin Colorectal Cancer; 2013 Jun; 12(2):86-94. PubMed ID: 23562587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
    Saif MW
    Anticancer Res; 2013 Jun; 33(6):2377-80. PubMed ID: 23749885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
    Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.
    Clarke JM; Hurwitz HI; Rangwala F
    Cancer Treat Rev; 2014 Oct; 40(9):1065-72. PubMed ID: 25047778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.
    Sanz-Garcia E; Saurí T; Tabernero J; Macarulla T
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):995-1004. PubMed ID: 25988772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An oncology nurses' guide to new targeted agents for metastatic colorectal cancer.
    McIntyre K
    Clin J Oncol Nurs; 2015 Oct; 19(5):571-9. PubMed ID: 26414575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.
    Khan K; Cunningham D; Chau I
    Curr Drug Targets; 2017; 18(1):56-71. PubMed ID: 25808652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.
    Tang PA; Cohen SJ; Kollmannsberger C; Bjarnason G; Virik K; MacKenzie MJ; Lourenco L; Wang L; Chen A; Moore MJ
    Clin Cancer Res; 2012 Nov; 18(21):6023-31. PubMed ID: 22977191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New molecular targeting drugs for metastatic colorectal cancer].
    Komatsu Y; Harada K; Fukushima H; Yuki S
    Nihon Rinsho; 2014 Jan; 72(1):120-6. PubMed ID: 24597359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Targeted therapies for metastatic colorectal cancer].
    Kito Y; Yamazaki K
    Nihon Rinsho; 2015 Aug; 73(8):1384-90. PubMed ID: 26281694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.
    Lee YC; Michael M; Zalcberg JR
    Expert Opin Investig Drugs; 2015; 24(10):1307-20. PubMed ID: 26212373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes.
    Gill S; Dowden S; Colwell B; Collins LL; Berry S
    Cancer Treat Rev; 2014 Dec; 40(10):1171-81. PubMed ID: 25458604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenesis agents in colorectal cancer.
    Hubbard J; Grothey A
    Curr Opin Oncol; 2010 Jul; 22(4):374-80. PubMed ID: 20375894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept in lung cancer.
    Neal JW; Wakelee HA
    Expert Opin Biol Ther; 2013 Jan; 13(1):115-20. PubMed ID: 23199019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to Manage the Side Effects of New Targets Agents for Metastatic Colorectal Cancer.
    Becze E
    ONS Connect; 2016 Jan; 31(1):24-5. PubMed ID: 26887105
    [No Abstract]   [Full Text] [Related]  

  • 20. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.